VAV1 (vav 1 oncogene) by Katzav, S









Atlas Genet Cytogenet Oncol Haematol. 2005; 9(1)  
 
21 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
VAV1 (vav 1 oncogene) 
Shulamit Katzav 
Experimental Medicine & Cancer Research, The Hebrew University/Hadassah Medical School, Ein-Karem, 
P.O.Box 12272, Jerusalem 91120, Israel (SK) 
 
Published in Atlas Database: January 2005 
Online updated version : http://AtlasGeneticsOncology.org/Genes/VAV1ID195ch19p13.html 
DOI: 10.4267/2042/38153 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2005 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: VAV  




2535 mRNA complete codons. 
Protein 
Note 
Vav1 was discovered when DNA from five esophageal 
carcinomas were tested for their transforming activity.  
This newly identified gene represented the sixth 
oncogene detected in Dr. Barbacid's laboratory and it 
was thus designated Vav1, after the sixth letter of the 
Hebrew alphabet. Vav1 was activated as an oncogene 
in vitro by replacement of 67 amino-acid residues of its 
amino-terminus (CH region) with 19 amino-acids 
residues of pSV2neo sequences, co-transfected as a 
selectable marker.  
Wild-type Vav1 produces minimal transformation of 
NIH3T3 murine fibroblasts only when the protein is 
grossly over-expressed.  
Removal of its amino terminus sequences (65 residue), 
thus mimicking its original mode of activation, is 
sufficient to induce Vav1 transformation. 
Description 
Vav1 encodes a highly unique protein that contains 
numerous modular motifs known to play a role in 
tyrosine-mediated signal transduction cascades, such as 
a dbl homology (DH) region, which exhibits a guanine 
nucleotide exchange factor (GEF) activity towards the
Rho family GTPases; a pleckstrin homology (PH) 
domain which interacts with polyphosphoinositides; a 
Src Homology 2 (SH2) and two Src Homology 3 (SH3) 
domains that mediate protein-protein interactions; a 
proline- rich motif that enables binding to SH3 -
containing proteins, an acidic-rich (Ac) region and a 
'calponin-homology' (CH) region, which functions as
an actin-binding domain in other proteins and two 
nuclear localization signals (NLS).  
In fact, Vav1 is the only known Rho GEF that 
combines in the same protein the DH/PH motifs and 
the structural hallmark of signal transducer proteins, the 
SH2 and SH3 domains. 
Expression 
Vav1 is specifically expressed in the hematopoietic 
system. 
Function 
The Vav1 protein (95 kDa) is rapidly tyrosine-
phosphorylated following stimulation of various 
receptors on hematopoietic cells (TCR, BCR, IgE, etc). 
Vav1 can then function in various signaling cascades.  
 











First, as a tyrosine-phosphorylated protein, Vav1 
operates as a guanine nucleotide exchange factor (GEF) 
for Rac1, Rac2 and RhoG. It is the only known GEF 
protein whose activity is regulated by tyrosine 
phosphorylation.  
As a regulator of activation of the Rho/Rac GTPases, 
Vav1 participates in several processes that require 
cytoskeletal reorganization, such as the formation of 
the immunological synapse (IS), phagocytosis, platelet 
aggregation and spreading. Vav1 can also function in 
GEF-independent pathways through its association 
with other proteins such as ZAP-70, SLP-76, Ly-GDI 
(an inhibitor of Rho/RacGTPases), Grb2 and 
cytoseketal proteins such as Zyxin.  
Vav1 plays a critical role in stimulation of NFAT 
(Nuclear Factor of Activated T cells), culminating in 
the production of numerous vital cytokines. Vav1 also 
leads to the induction of an intracellular calcium flux 
by regulating the activation of phospholipase Cg1 
(PLCg1) via phosphoinositide 3-kinase (PI3K) 
dependent and -independent pathways. The activity of 
Vav1 also leads to the activation of NF-kB and the 
extracellular signal regulated kinase (ERK) mitogen-
activated protein kinase (MAPK) signaling cascade.  
There is compelling evidence from studies of gene-
targeted mice to indicate that Vav1 participates in the 
development and function of many types of immune 
cell such as the positive- and negative-selection events 
that are imposed on double-positive thymocytes. 
Homology 
Vav1 is one of a larger family of proteins that include 
Vav2 and Vav3 which unlike Vav1 are also 
ubiquitously expressed and the Vav homologues in 
Drosophila Melanogaster and in the nematode, C. 
elegans. These proteins are similar in their structu e o 




Although, no mutants of Vav1 have been reported thus
far in "real" human tumors, it was recently found that 
Vav1 is expressed in the majority of 42 specimens of 
human neuroblastoma, suggesting a possible  
 
 
involvement of this protein in the neoplastic process in  
a subset of neuroblastomas. Furthermore, it was 
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